New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats.

Ma YL, Bryant HU, Zeng Q, Schmidt A, Hoover J, Cole HW, Yao W, Jee WS, Sato M

Endocrinology1 May 2003Cited by 69 (Europe PMC)

PMID12697709DOI10.1210/en.2002-221061PepBankPUB-12697709

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

2 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats previously receiving vehicle, teriparatide increased lumbar vertebral bone mineral density by 18% versus pretreatment levels.
In plain wordsIn rats previously receiving vehicle, teriparatide increased vertebral bone density compared with pretreatment levels.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar vertebral BMD after vehicle pretreatment
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Levels after 10 months, before teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 microg/kg per day · 2 monthsAs given in this study (rat).
Measurements
BMD increase
18%
vehicle/teriparatide versus 10-month levels
Source sentences
Summary
After 2 months of teriparatide treatment, lumbar vertebra showed relative bone mineral density increases of 18%, 7%, 11%, and 10% for vehicle/teriparatide, ABP/teriparatide, EE/teriparatide, and Ral/teriparatide, respectively, compared with 10 month levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague Dawley rats were Ovx and treated with ABP (28 microg/kg, twice weekly), EE (0.1 mg/kg per d), or Ral (1 mg/kg per d) for 10 months before switching to teriparatide 30 microg/kg per d for another 2 months.
Report a problemFND-1269770901
02AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats previously receiving vehicle, teriparatide increased trabecular area by 105% versus pretreatment levels.
In plain wordsIn rats previously receiving vehicle, teriparatide increased trabecular bone area compared with pretreatment levels.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular area after vehicle pretreatment
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Levels after 10 months, before teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 microg/kg per day · 2 monthsAs given in this study (rat).
Measurements
Trabecular area increase
105%
vehicle/teriparatide versus 10-month levels
Source sentences
Summary
Histomorphometry showed that trabecular area was increased by 105%, 113%, 36%, and 48% for vehicle/teriparatide, ABP/teriparatide, EE/teriparatide, and Ral/teriparatide, respectively, compared with 10 month levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague Dawley rats were Ovx and treated with ABP (28 microg/kg, twice weekly), EE (0.1 mg/kg per d), or Ral (1 mg/kg per d) for 10 months before switching to teriparatide 30 microg/kg per d for another 2 months.
Report a problemFND-1269770905

Studies that did not test the peptide alone11

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

03AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, alendronate followed by teriparatide increased lumbar vertebral bone mineral density by 7% versus levels before the switch.
In plain wordsIn rats, alendronate followed by teriparatide increased vertebral bone density compared with levels before the switch.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar vertebral BMD after alendronate pretreatment
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Levels after 10 months, before teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD increase
7%
ABP/teriparatide versus 10-month levels
Source sentences
Summary
After 2 months of teriparatide treatment, lumbar vertebra showed relative bone mineral density increases of 18%, 7%, 11%, and 10% for vehicle/teriparatide, ABP/teriparatide, EE/teriparatide, and Ral/teriparatide, respectively, compared with 10 month levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague Dawley rats were Ovx and treated with ABP (28 microg/kg, twice weekly), EE (0.1 mg/kg per d), or Ral (1 mg/kg per d) for 10 months before switching to teriparatide 30 microg/kg per d for another 2 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1269770902
04AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, estrogen followed by teriparatide increased lumbar vertebral bone mineral density by 11% versus levels before the switch.
In plain wordsIn rats, estrogen followed by teriparatide increased vertebral bone density compared with levels before the switch.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar vertebral BMD after estrogen pretreatment
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Levels after 10 months, before teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD increase
11%
EE/teriparatide versus 10-month levels
Source sentences
Summary
After 2 months of teriparatide treatment, lumbar vertebra showed relative bone mineral density increases of 18%, 7%, 11%, and 10% for vehicle/teriparatide, ABP/teriparatide, EE/teriparatide, and Ral/teriparatide, respectively, compared with 10 month levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague Dawley rats were Ovx and treated with ABP (28 microg/kg, twice weekly), EE (0.1 mg/kg per d), or Ral (1 mg/kg per d) for 10 months before switching to teriparatide 30 microg/kg per d for another 2 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1269770903
05AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, raloxifene followed by teriparatide increased lumbar vertebral bone mineral density by 10% versus levels before the switch.
In plain wordsIn rats, raloxifene followed by teriparatide increased vertebral bone density compared with levels before the switch.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar vertebral BMD after raloxifene pretreatment
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Levels after 10 months, before teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD increase
10%
Ral/teriparatide versus 10-month levels
Source sentences
Summary
After 2 months of teriparatide treatment, lumbar vertebra showed relative bone mineral density increases of 18%, 7%, 11%, and 10% for vehicle/teriparatide, ABP/teriparatide, EE/teriparatide, and Ral/teriparatide, respectively, compared with 10 month levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague Dawley rats were Ovx and treated with ABP (28 microg/kg, twice weekly), EE (0.1 mg/kg per d), or Ral (1 mg/kg per d) for 10 months before switching to teriparatide 30 microg/kg per d for another 2 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1269770904
06AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, alendronate followed by teriparatide increased trabecular area by 113% versus levels before the switch.
In plain wordsIn rats, alendronate followed by teriparatide increased trabecular bone area compared with levels before the switch.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular area after alendronate pretreatment
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Levels after 10 months, before teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Trabecular area increase
113%
ABP/teriparatide versus 10-month levels
Source sentences
Summary
Histomorphometry showed that trabecular area was increased by 105%, 113%, 36%, and 48% for vehicle/teriparatide, ABP/teriparatide, EE/teriparatide, and Ral/teriparatide, respectively, compared with 10 month levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague Dawley rats were Ovx and treated with ABP (28 microg/kg, twice weekly), EE (0.1 mg/kg per d), or Ral (1 mg/kg per d) for 10 months before switching to teriparatide 30 microg/kg per d for another 2 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1269770906
07AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, estrogen followed by teriparatide increased trabecular area by 36% versus levels before the switch.
In plain wordsIn rats, estrogen followed by teriparatide increased trabecular bone area compared with levels before the switch.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular area after estrogen pretreatment
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Levels after 10 months, before teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Trabecular area increase
36%
EE/teriparatide versus 10-month levels
Source sentences
Summary
Histomorphometry showed that trabecular area was increased by 105%, 113%, 36%, and 48% for vehicle/teriparatide, ABP/teriparatide, EE/teriparatide, and Ral/teriparatide, respectively, compared with 10 month levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague Dawley rats were Ovx and treated with ABP (28 microg/kg, twice weekly), EE (0.1 mg/kg per d), or Ral (1 mg/kg per d) for 10 months before switching to teriparatide 30 microg/kg per d for another 2 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1269770907
08AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, raloxifene followed by teriparatide increased trabecular area by 48% versus levels before the switch.
In plain wordsIn rats, raloxifene followed by teriparatide increased trabecular bone area compared with levels before the switch.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular area after raloxifene pretreatment
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Levels after 10 months, before teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Trabecular area increase
48%
Ral/teriparatide versus 10-month levels
Source sentences
Summary
Histomorphometry showed that trabecular area was increased by 105%, 113%, 36%, and 48% for vehicle/teriparatide, ABP/teriparatide, EE/teriparatide, and Ral/teriparatide, respectively, compared with 10 month levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague Dawley rats were Ovx and treated with ABP (28 microg/kg, twice weekly), EE (0.1 mg/kg per d), or Ral (1 mg/kg per d) for 10 months before switching to teriparatide 30 microg/kg per d for another 2 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1269770908
09AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, regimens ending with teriparatide enhanced mineralizing surface across all pretreatment groups.
In plain wordsIn rats, regimens ending with teriparatide increased mineralizing bone surface across pretreatment groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMineralizing surface across pretreatment groups
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Levels after 10 months, before teriparatide
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Teriparatide enhanced mineralizing surface, mineral apposition rate, and bone formation rate in all groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague Dawley rats were Ovx and treated with ABP (28 microg/kg, twice weekly), EE (0.1 mg/kg per d), or Ral (1 mg/kg per d) for 10 months before switching to teriparatide 30 microg/kg per d for another 2 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1269770909
10AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, regimens ending with teriparatide enhanced mineral apposition rate across all pretreatment groups.
In plain wordsIn rats, regimens ending with teriparatide increased the rate of mineral deposition across pretreatment groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMineral apposition rate across pretreatment groups
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Levels after 10 months, before teriparatide
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Teriparatide enhanced mineralizing surface, mineral apposition rate, and bone formation rate in all groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague Dawley rats were Ovx and treated with ABP (28 microg/kg, twice weekly), EE (0.1 mg/kg per d), or Ral (1 mg/kg per d) for 10 months before switching to teriparatide 30 microg/kg per d for another 2 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1269770910
11AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, regimens ending with teriparatide enhanced bone formation rate across all pretreatment groups.
In plain wordsIn rats, regimens ending with teriparatide increased bone formation rate across pretreatment groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone formation rate across pretreatment groups
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Levels after 10 months, before teriparatide
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Teriparatide enhanced mineralizing surface, mineral apposition rate, and bone formation rate in all groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague Dawley rats were Ovx and treated with ABP (28 microg/kg, twice weekly), EE (0.1 mg/kg per d), or Ral (1 mg/kg per d) for 10 months before switching to teriparatide 30 microg/kg per d for another 2 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1269770911
12AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, regimens ending with teriparatide improved vertebral peak load similarly across pretreatment groups versus levels before the switch.
In plain wordsIn rats, regimens ending with teriparatide increased vertebral strength similarly across pretreatment groups compared with earlier levels.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral peak load across pretreatment groups
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Levels after 10 months, before teriparatide
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Compression testing of vertebra showed that teriparatide improved strength (peak load) and toughness in all groups to a proportionately similar extent compared with 10 month levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague Dawley rats were Ovx and treated with ABP (28 microg/kg, twice weekly), EE (0.1 mg/kg per d), or Ral (1 mg/kg per d) for 10 months before switching to teriparatide 30 microg/kg per d for another 2 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1269770912
13AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, regimens ending with teriparatide improved vertebral toughness similarly across pretreatment groups versus levels before the switch.
In plain wordsIn rats, regimens ending with teriparatide increased vertebral toughness similarly across pretreatment groups compared with earlier levels.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral toughness across pretreatment groups
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Levels after 10 months, before teriparatide
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Compression testing of vertebra showed that teriparatide improved strength (peak load) and toughness in all groups to a proportionately similar extent compared with 10 month levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Sprague Dawley rats were Ovx and treated with ABP (28 microg/kg, twice weekly), EE (0.1 mg/kg per d), or Ral (1 mg/kg per d) for 10 months before switching to teriparatide 30 microg/kg per d for another 2 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1269770913

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.